Format

Send to

Choose Destination
PLoS One. 2017 Apr 24;12(4):e0176395. doi: 10.1371/journal.pone.0176395. eCollection 2017.

miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.

Zhou W1,2,3, Song F3,4, Wu Q3,4, Liu R3, Wang L2, Liu C2, Peng Y2, Mao S5, Feng J1,2, Chen C3.

Author information

1
Third Clinical College, Southern Medical University, Guangdong Province, Guangzhou, China.
2
Department of Laboratory Medicine & Central Laboratory, Southern Medical University Affiliated Fengxian Hospital, Shanghai, China.
3
Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Kunming Institute of Zoology, Chinese Academy of Sciences, Yunnan Province, Kunming, China.
4
Department of Laboratory Medicine & Central Laboratory, Jinzhou Medical University Affiliated Fengxian Hospital, Shanghai, China.
5
Hubei University of Medicine Affiliated Taihe Hospital, Hubei Province, Shiyan, China.

Abstract

Triple negative breast cancer (TNBC) is one of the most aggressive breast cancers without effective targeted therapies. Numerous studies have implied that KLF5 plays an important roles in TNBC. How is KLF5 regulated by microRNAs has not been well studied. Here, we demonstrated that miR-217 down-regulates the expression of KLF5 and KLF5's downstream target gene FGF-BP and Cyclin D1 in TNBC cell lines HCC1806 and HCC1937. Consequently, miR-217 suppresses TNBC cell growth, migration, and invasion. MiR-217 suppresses TNBC, at least partially, through down-regulating the KLF5 expression. These results suggest that the miR-217-KLF5 axis might serve as a potential target for treatment of TNBC.

PMID:
28437471
PMCID:
PMC5402967
DOI:
10.1371/journal.pone.0176395
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center